Company Description
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial.
In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie.
IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Yujiro Hata |
Contact Details
Address: 5000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 443 6209 |
| Website | ideayabio.com |
Stock Details
| Ticker Symbol | IDYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 1676725 |
| CUSIP Number | 45166A102 |
| ISIN Number | US45166A1025 |
| Employer ID | 47-4268251 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yujiro S. Hata | Founder, President, Chief Executive Officer and Director |
| Andres Ruiz Briseno CPA | Chief Accounting Officer |
| Dr. Michael A. White Ph.D. | Chief Scientific Officer |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer |
| Stuart C. Dorman | Chief Commercial Officer |
| Dr. Joshua Bleharski Ph.D. | Chief Financial Officer |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer |
| Douglas B. Snyder | Chief Legal Officer |
| Francine Zelaya | Senior Vice President and Head of Human Resources |
| Mick O'Quigley | Senior Vice President of Medical Writing and Project Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 8, 2026 | SCHEDULE 13G/A | Filing |
| Dec 12, 2025 | 8-K | Current Report |
| Dec 5, 2025 | 8-K | Current Report |